Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for long-term vandetanib therapy in this setting, in addition to treatment for disease-related symptoms, effective management of related adverse events (AEs) is vital to ensure patient compliance and maximize clinical benefit with vandetanib therapy.
This expert meeting-based review aims to summarize published data on AEs associated with vandetanib therapy and to provide clinicians with specific practical guidance on education, monitoring, and management of toxicities induced in patients treated with vandetanib in advanced and metastatic MTC. The content of this review is based on the expert discussions from a multidisciplinary meeting held in October 2012.
Characteristics, frequency, and risk data are outlined for a number of dermatological, cardiovascular, gastrointestinal, and general AEs related to vandetanib treatment. Preventive strategies, practical treatment suggestions, and points for clinical consideration are provided.
Good patient and team communication is necessary for the prevention, early detection, and management of AEs of vandetanib. Physicians, nurses, and other healthcare providers play a critical role in providing AE management and patient support to optimize outcomes with vandetanib in MTC.
- Schlumberger M, Bastholt L, Dralle H, et al. European Thyroid Association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1:5–14. CrossRef
- Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134–42. CrossRef
- Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284–90.
- Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62:4645–55.
- AstraZeneca 2012. Caprelsa (vandetanib) tablets: US prescribing information. http://www.astrazeneca-us.com/pi/caprelsa.pdf (Accessed Sep 10, 2013).
- European Medicines Agency (EMA) 2012. Caprelsa (vandetanib): Summary of Product Characteristics, AstraZeneca. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002315/WC500123555.pdf (Accessed Sep 10, 2013).
- Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134–41. CrossRef
- Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767–72. CrossRef
- Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897–905. CrossRef
- Brassard M, Neraud B, Trabado S, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab. 2011;96:2741–9. CrossRef
- Langmuir PB, Yver A. Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther. 2012;91:71–80. CrossRef
- Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS ONE. 2012;7:e30353. CrossRef
- Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18:3722–30. CrossRef
- Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34:221–37. CrossRef
- Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2664–71. CrossRef
- Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:1125–33. CrossRef
- Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148:1418–20. CrossRef
- Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer. 2012;20:909–21. CrossRef
- Stahli BE, Schwab S. Amiodarone-induced skin hyperpigmentation. QJM. 2011;104:723–4.
- Yoon J, Oh CW, Kim CY. Stevens–Johnson syndrome induced by vandetanib. Ann Dermatol. 2011;23:S343–5. CrossRef
- Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116:3916–23. CrossRef
- Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007;72:152–9. CrossRef
- Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–95. CrossRef
- Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610–21. CrossRef
- Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18:509–22. CrossRef
- National Cancer Institute 2010. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 (Accessed Nov 22, 2012).
- Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol. 2013;75:919–30. CrossRef
- Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012;19:403–88. CrossRef
- Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2013;76:48–57. CrossRef
- Chan A, Isbister GK, Kirkpatrick CM, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM. 2007;100:609–15. CrossRef
- Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31–50. CrossRef
- Arizona Center for Education and Research on Therapeutics (AZERT). CredibleMeds(R) website. http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs (Accessed Sep 10, 2013).
- Hafermann MJ, Namdar R, Seibold GE, Page RL. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53–8.
- Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004;15:330–7. CrossRef
- European Medicines Agency (EMA) 2010. Aloxi (palonosetron) Summary of Product Characteristics, Helsinn Birex Pharmaceuticals Ltd. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000563/WC500024259.pdf (Accessed Sep 10, 2013).
- Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer. 2012;20:1435–9. CrossRef
- Yavas C, Dogan U, Yavas G, Araz M, Ata OY. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer. 2012;20:2343–7. CrossRef
- Rumore MM. Cardiovascular adverse effects of metoclopramide: review of literature. Int J Case Rep Images. 2012;3:1–10. CrossRef
- European Medicines Agency (EMA) 2008. Emend (aprepitant) Summary of Product Characteristics, Merck Sharp & Dohme. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000527/WC500026537.pdf (Accessed Sep 10, 2013).
- Food and Drug Administration (FDA) 2003. Aprepitant FDA Advisory Committee Background Package. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3928B1_01_Merck%20Backgrounder.pdf (Accessed Sep 10, 2013).
- Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo controlled study. J Clin Endocrinol Metab. 2013;98:2401–8. CrossRef
- Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Advances in Therapy
Volume 30, Issue 11 , pp 945-966
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Adverse effects
- Antineoplastic agents/adverse effects
- Medullary thyroid cancer
- Medullary thyroid carcinoma
- Patient safety
- Piperidines/therapeutic use
- Protein kinase inhibitors
- Thyroid neoplasms/drug therapy
- Industry Sectors
- Author Affiliations
- 1. Servicio de Oncología Médica, Hospital Ramón y Cajal, Carretera de Colmenar Viejo Km. 9.100, 28034, Madrid, Spain
- 11. Department of Nuclear Medicine, Central Hospital of Augsburg, Augsburg, Germany
- 2. Department of Nuclear Medicine, University Hospital of Wuerzburg, Wuerzburg, Germany
- 3. Department of Internal Medicine and Medical Specialities, University of Rome “Sapienza”, Rome, Italy
- 4. Thyroid Unit, Royal Marsden Hospital, Surrey, UK
- 5. Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
- 6. Department of Medical Oncology, Dermatology Unit and INSERM U981, Gustave Roussy Institute, University of Paris-Sud, Villejuif, France
- 7. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute, University of Paris-Sud, Villejuif, France
- 8. Department of Oncology, Clinical Research Unit, Odense University Hospital, Odense, Denmark
- 9. Cardiology Service, Hospital Ramón y Cajal, Madrid, Spain
- 10. Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain